Molecular surveillance of chloroquine resistance in Plasmodium vivax isolates from malaria cases in Yunnan Province of China using pvcrt-o gene polymorphisms
-
Published:2023-11-08
Issue:1
Volume:22
Page:
-
ISSN:1475-2875
-
Container-title:Malaria Journal
-
language:en
-
Short-container-title:Malar J
Author:
Ding Hongyun,Dong Ying,Deng Yan,Xu Yanchun,Liu Yan,Wu Jing,Chen Mengni,Zhang Canglin,Liu Li,Lin Yingkun
Abstract
Abstract
Background
The efficacy of chloroquine treatment for vivax malaria has been rarely evaluated due to a lack of an appropriate testing method. The objective of this study was to conduct molecular monitoring of chloroquine resistance in Plasmodium vivax strains from vivax malaria patients in Yunnan Province, focusing on the analysis of polymorphism in the P. vivax chloroquine resistance transporter protein orthologous gene (pvcrt-o).
Methods
In accordance with the principles of a cohort study, blood samples were collected from malaria cases diagnosed with a P. vivax mono-infection in Yunnan Province from 2020 to 2022. Segmental PCR was used to amplify the whole pvcrt-o gene in the blood samples and their products were subsequently sequenced. The sequencing data were arranged to obtain the full coding DNA sequence (CDS) as well as the gene’s promoter region sequences. The CDSs were aligned with the reference sequence (XM_001613407.1) of the P. vivax SalI isolate to identify the mutant loci.
Results
From a total of 375 blood samples taken from vivax malaria cases, 272 both whole gene CDSs (1272–1275 bp) and promoter DNA sequences (707 bp) of pvcrt-o gene were obtained. Among the whole CDSs, there were 7 single nucleotide polymorphic sites in which c.7 A>G was the minor allele frequency (MAF) site with 4.4% (12/272) detection rate. The mutation detection rate showed a significant decrease from 9.8% (10/102) in 2020 to 1.1% (1/92) in 2021 and 1.3% (1/78) in 2022, indicating statistical significance (χ2 = 11.256, P < 0.05). Among the identified 12 haplotypes, the majority of which were wild type (75.7%; 206/272). These four mutant haplotypes (Hap_3, Hap_5, Hap_9, and Hap_10) were classified as “K10 insertion type” and accounted for 12.1% (33/272). The detection rate of Hap_3 increased from 1.0% (1/102) in 2020 to 13.0% (12/92) in 2021 and 14.1% (11/78) in 2022, indicating statistical significance. A total of 23.8% (65/272) of the samples exhibited 14 bp (bp) deletions in the promoter region, occurring most frequently in the wild type haplotype (Hap_1) samples at a rate of 28.6% (59/206).
Conclusions
In recent years in Yunnan Province, a notable proportion of vivax malaria patients are infected by P. vivax strains with a “K10 insertion” and partial sequence deletions in the promoter region of the pvcrt-o gene, necessitating vigilance.
Funder
National Science Foundation, China
Yunnan Major Scientific and Technological Projects
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Parasitology
Reference63 articles.
1. Coatney GR. Pitfalls in a discovery: the chronicle of chloroquine. Am J Trop Med Hyg. 1963;12:121–8.
2. Thompson PE, Werbel LM. Antimalarial agents: chemistry and pharmacology. In: DeStevens G, editor. Medicinal chemistry, vol. 12. New York: Academic Press; 1972.
3. Payne D. Spread of chloroquine resistance in Plasmodium falciparum. Parasitol Today. 1987;3:241–6.
4. Che LG, Chen WC, Yang HL. Geographical distribution of chloroquine-resistant strains of malignant malaria in Yunnan Province. Chin J Parasitol Parasit Dis. 1986;7:88–91 (in Chinese).
5. Yang HL, Yang PF, Dong Y, Che LG, He H, Liu DQ, et al. Longitudinal monitoring of chloroquine resistance of Plasmodium falciparum in Yunnan Province. Chin J Parasitol Parasit Dis. 1994;12:33–5 (in Chinese).